No Data
No Data
Swhy: The penetration rate continues to increase coupled with the rise of domestic products, bullish on the cosmetic and medical beauty sector.
The medical beauty industry will continue to benefit from a rich supply of products and maintain healthy development through industry standardization.
Lushang Freda Pharmaceutical (600223.SH) currently does not conduct direct sales business.
Lushang Freda pharmaceutical (600223.SH) stated on the interactive platform on July 5 that the company is currently not engaged in direct sales business and has not cooperated with any company to use its license.
CITIC Securities: the collagen industry's prosperity continues with significant growth among various leading companies, and there is ample potential for the future.
According to the Zhitong Finance APP, Citic Securities research report believes that the sales of restructured collagen products have been excellent, with brands such as Weweima, Kelifu, and Viyimi performing well this year.
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Lushang Freda PharmaceuticalLtd (SHSE:600223) has had a rough three months with its share price down 22%. But if you pay close attention, you might find that its key financial indicators look quite
Guosen Securities: differentiation on the 618 promotion platform, stable progress in domestic beauty and cosmetics industry leader.
The rules for the 618 promotion have been simplified, and sales performance through live streaming has been under pressure.
Is Now The Time To Look At Buying Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223), might not be a large cap stock, but it received a lot of attention from a substantial price movement on the SHSE over the last few months, inc
No Data